Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Allergan Deal Inches Forward with Court’s Decision

By Pharmaceutical Processing | November 4, 2014

In a win for Valeant and Pershing Square, a federal judge has decided that they can vote in takeover target Allergan’s upcoming shareholder meeting.

Botox maker Allergan said in a statement Tuesday that it will file an emergency appeal.

Valeant Pharmaceuticals International Inc. and Pershing Square Capital Management, run by activist investor Bill Ackman, have made several offers for Allergan since April but have been rebuffed. Valeant’s most recent offer amounted to about $53 billion. It has indicated that it is willing to go higher.

Allergan is holding a special meeting on Dec. 18. Shareholders can vote then on whether to replace the Irvine, California-based company’s directors. A change in leadership could increase support for the deal.

Allergan had sought a court order that barred Valeant and Pershing from voting their shares and accused both parties of violating securities regulations.

The California court said Tuesday that while Allergan raised “serious questions” about the legality of some actions by Valeant and Pershing, it decided they can vote if they make certain disclosures about their trading activity and relationship.

“Although there is something inherently appealing about preventing someone who may have violated the securities laws from using their allegedly wrongfully acquired shares to carry out their ultimate plan … the Court does not believe such an injunction is appropriate at this time and in this case,” Judge David Carter wrote in his decision.

Shares of the Allergan rose $1.98 to close at $195.12 Tuesday. Valeant shares added 76 cents to close at $133.61.

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE